JNTU B.Pharmacy III Year INDUSTRIAL PHARMACY-I Previous Question Paper (October/November-2020 - R17)

The physical form of a drug substance, specifically its polymorphism, crystallinity, and amorphous state, is critical in preformulation as it directly influences physicochemical properties such as solubility, dissolution rate, stability, and bioavailability.

• Solubility and Dissolution Rate: Different crystalline forms (polymorphs) possess varying lattice energies. Metastable forms generally exhibit higher solubility and faster dissolution rates compared to stable forms, which is essential for enhancing the oral absorption of poorly water-soluble drugs.
• Stability: The thermodynamic stability of a drug form determines its shelf-life. A metastable form may undergo spontaneous conversion to a more stable form during storage, potentially leading to precipitation in liquid formulations or changes in dissolution profiles in solid dosage forms.
• Bioavailability: Since dissolution is often the rate-limiting step for absorption, the choice of physical form is a primary determinant of the drug's therapeutic efficacy.
• Processing Characteristics: The physical form affects flowability, compressibility, and hygroscopicity, which are vital for successful tablet compression and capsule filling.

The Biopharmaceutics Classification System (BCS) classifies drug substances into four categories based on their aqueous solubility and intestinal permeability:

• Class I: High Solubility, High Permeability.
• Class II: Low Solubility, High Permeability.
• Class III: High Solubility, Low Permeability.
• Class IV: Low Solubility, Low Permeability.

The importance of BCS in preformulation studies includes:

• Formulation Strategy: For Class II drugs, preformulation focuses on solubility enhancement techniques like micronization, solid dispersions, or complexation. For Class III drugs, the focus shifts to permeability enhancers or specialized delivery systems.
• In vitro-In vivo Correlation (IVIVC): BCS helps predict the likelihood of establishing a meaningful correlation between dissolution data and clinical performance.
• Regulatory Guidance: It provides a scientific basis for biowaivers, allowing for the approval of generic products without conducting expensive and time-consuming human bioequivalence studies under specific conditions.
• Resource Allocation: It allows scientists to prioritize formulation efforts by identifying which drugs require complex delivery technologies versus those that can be developed using standard manufacturing processes.